RUNX3 and neoplasm: Although both Runx2 and Runx3 activity are required to promote the differentiation of cytotoxic CD8+CD103+CD49a+TRM cells, providing immunosurveillance of infected and malignant cells [116], emerging research suggests that tumor‐specific CD8+TRM cells exhibit a residency profile that diverges from traditional markers associated with CD8+TRM cells, such as CD49a and CD69.